697304-01-1

Upstream product

• 697304-21-5 ethyl (2R,3S)-3-(1H-indol-3-yl)-2-{[(4-phenylpiperidin-1-yl)carbonyl]amino}butanoate 

Downstream Products

• 697308-16-0 N-{(1R,2S)-2-(1H-indol-3-yl)-1-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-ylamino)carbonyl]propyl}-4-phenylpiperidine-1-carboxamide 
• 697308-94-4 N-[(1R,2S)-1-[({2-(aminocarbonyl)-5-[(dimethylamino)methyl]phenyl}amino)carbonyl]-2-(1H-indol-3-yl)propyl]-4-phenylpiperidine-1-carboxamide 
• 697306-65-3 N-[(1R,2S)-1-({6-[(dimethylamino)methyl]-2,3-dihydro-4H-1,4-benzoxazin-4-yl}carbonyl)-2-(1H-indol-3-yl)propyl]-4-phenyl-1-piperidinecarboxamide 
• 697306-85-7 N-[(1R,2S)-1-{[6-(aminomethyl)-2,3-dihydro-1H-indol-1-yl]carbonyl}-2-(1H-indol-3-yl)propyl]-4-phenyl-1-piperidinecarboxamide 
• 697307-16-7 N-((1R,2S)-1-(((3-((dimethylamino)methyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-phenyl-1-piperidinecarboxamide 
• 697307-70-3 N-[(1R,2S)-1-({5-[(dimethylamino)methyl]-2-ethoxyphenyl}aminocarbonyl)-2-(1H-indol-3-yl)propyl]-4-phenyl-1-piperidinecarboxamide 

Relevant academic research and scientific papers

A practical synthesis of enantiopure β-methyltryptophan ethyl ester for a preparation of diabetes drug

A practical synthesis of (2R,3S)- and (2S,3R)-β-methyltryptophan ethyl ester (β-MeTrp-OEt) has been developed. Racemic threo-β-MeTrp-OEt was diastereoselectively prepared via crystallization-induced diastereomer transformation (CIDT) of the α-nitro equiva

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.